HaberlerBenzingaReported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients Benzinga 2026.10.05 06:57 (GMT+0) Benzinga kaynağında aç Diğer haberler MKS Inc. EVP Renee Donlan 438.040 dolarlık hisse sattı International Bancshares hissesi 64,20 dolarla 52 haftalık dibe vurdu Novanta Inc hissesi 47,83 dolarda 52 haftalık dip yaptı Provident Financial Holdings’te yönetim kurulu seçildi First Solar CEO’su ABD üretim stratejisi hakkında ifade verdi Team Inc. CEO’su Gary Hill 150.000 dolarlık hisse satın aldı